Income Statement (TTM)
NAVCO Pharmaceuticals Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2021 09-30 |
2022 09-30 |
2023 06-30 |
|
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Change (%) | 278.32 | -91.15 | |
| % of Revenue | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | |||
| Change (%) | |||
| % of Revenue | |||
| Gross Operating Profit | 0 | 0 | 0 |
| Change (%) | 278.32 | -91.15 | |
| % of Revenue | 100.00 | 100.00 | 100.00 |
| SG&A | 0 | 0 | 1 |
| Change (%) | -6.23 | 60.95 | |
| % of Revenue | 3,194.74 | 791.88 | 14,396.06 |
| R&D | |||
| Change (%) | |||
| % of Revenue | |||
| OpEx | 1 | 1 | 1 |
| Change (%) | -3.86 | 55.40 | |
| % of Revenue | 3,409.64 | 866.48 | 15,208.63 |
| Operating Income | -1 | -0 | -1 |
| Change (%) | -12.39 | 74.52 | |
| % of Revenue | -3,309.64 | -766.48 | -15,108.63 |
| Interest Expense | -0 | -0 | -0 |
| Change (%) | 20.16 | 0.37 | |
| % of Revenue | -80.11 | -25.44 | -288.46 |
| Net Income | -1 | -0 | -4 |
| Change (%) | -11.62 | 675.24 | |
| % of Revenue | -3,389.75 | -791.92 | -69,343.75 |
Source: Capital IQ
